1. Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3). (October 2016) Authors: Ahmann, Andrew; Capehorn, Matthew; Charpentier, Guillaume; Dotta, Francesco; Henkel, Elena; Lingvay, Ildiko; Gaarsdal Holst, Anders; Annett, Miriam; Aroda, Vanita Journal: Diabetes research and clinical practice Issue: Volume 120(2016)Supplement 1 Page Start: S51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗